Document is current

Article History

Received: 11 December 2023

Accepted: 31 December 2023

First Online: 11 February 2024

Declarations

:

: Javier Puente has received study funding from Roche and Pfizer; consulting fees from Pfizer, Roche, Eisai, AstraZeneca, Janssen, and Gilead; honoraria for lectures from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Janssen, Merck, MSD, and Pfizer; support for travel from Janssen, Merck, and Pfizer; and has participated on an advisory board for AstraZeneca, BMS, Gilead, Janssen, Merck, MSD, and Pfizer. Oscar Buisán Rueda has received honoraria for lectures from Astellas, Janssen, and Bayer; and support for travel from Casen Recordati, Bayer, and Astellas. Ignacio Durán has received research grants from Roche and AstraZeneca; honoraria for lectures from Bristol Myers Squibb, MSD, Ipsen, Roche-Genentech, Janssen, Astellas Pharma, EUSA Pharma, Bayer, Novartis, Gilead, and Bayer; support for travel from MSD, Pfizer, Ipsen, Janssen, Bayer, and AstraZeneca; materials from Janssen; medical writing support from Roche-Genentech; and has participated on an advisory board for Bristol Myers Squibb, MSD, Ipsen, Roche-Genentech, Astellas Pharma, EUSA Pharma, Bayer, Novartis, Eisai, Debiopharm, Pharmacyclics, and Gilead. He has a leadership or fiduciary role in GO NORTE, Germ Cell Spanish Group, and GUARD consortium. Juan José Fernández Ávila has received honoraria for lectures from Astellas, Astra Zeneca, GSK, Janssen, and Bayer; and support for attending meetings and congresses from Janssen, Astellas, and Bayer. Alfonso Gómez-Iturriaga has received honoraria for lectures from Astellas Pharma, Bayer, Janssen, Ipsen, Novartis, and Casen Recordati; support for travel from Ipsen and Casen Recordati; and has participated on an advisory board for Astellas Pharma, Bayer, Janssen, and Elekta. Gemma Sancho Pardo has received honoraria for lectures from Astellas, Janssen, and Bayer; support for attending meetings and congresses from Janssen, Astellas, Ipsen, and Casen Recordati; and has participated on an advisory board for Janssen. Daniel Pérez Fentes has received honoraria for lectures from Astellas Pharma, Janssen, and Bayer; support for attending meetings and congresses from Astellas, Janssen, Bayer, Ipsen, and Casen Recordati; and has participated on advisory boards for Janssen, Astellas Pharma, and Bayer. Juan Antonio Vallejo Casas reports receiving research funding from Sanofi, EISAI, GE, and Curium; speaker´s bureau from Sanofi, Novartis, Bayer, Eisai, and Pfizer; and consulting fees from Sanofi, Bayer, Novartis, Janssen, and Fundación BBVA. Ferrán Algaba Arrea, Daniel Castellano Gauna, Mariano José Parada Blázquez, Paula Gratal, María Teresa Pardo, and Vicente Guillem Porta report no conflict of interest.

: This study did not involve humans and did not require approval by an Ethical Committee.

: This study did not involve humans and informed consent was not necessary.